The DOI matches its Crossref record; 136 of the 139 references it cites were found in a registry or an index.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Open accessAbstract
The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EPI-CT also evaluated risk using the revised World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignancies27,28.”
From Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults (2023) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“For CML patients, disease diagnosis and progression were defined according to the 2016 edition of World Health Organization criteria.75”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Self-citationClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citationRevised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Self-citationEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 2,011
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citationGrimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936
Cited by
Sorted by citations
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,938
Self-citationWHO classification of haematolymphoid tumours
Gaillard, F., & Gerstenmaier, J. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,763
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., Dinardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,633
Self-citationArber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E. A., Abel, M. L., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,359
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
de Kouchkovsky, I., & Abdul‐Hay, M. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.50 · Cited by 1,359
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul‐Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,353
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease
Beck, D. B., Ferrada, M. A., Sikora, K. A., Ombrello, A. K., Collins, J. C., Pei, W., Balanda, N. J., Ross, D. L., Cardona, D. O., Wu, Z., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026834 · Cited by 1,228
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N. G., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0357-9 · Cited by 1,106
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis, R. M., Wang, R., Davidoff, A. J., Ma, X., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.005 · Cited by 980
Prediction of acute myeloid leukaemia risk in healthy individuals
Abelson, S., Collord, G., Ng, S. W. K., Weissbrod, O., Mendelson Cohen, N., Niemeyer, E., Barda, N., Zuzarte, P. C., Heisler, L., Sundaravadanam, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0317-6 · Cited by 850
Short, N. J., Rytting, M., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 862
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 834
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Wei, A. H., Montesinos, P., Ivanov, V., Dinardo, C. D., Novák, J., Laribi, K., Kim, I., Stevens, D. A., Fiedler, W., Pagoni, M. N., et al. (2020) · Blood · doi:10.1182/blood.2020004856 · Cited by 793
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 797
“The European Society of Rheumatology (EULAR) in 2019 equated the application of JAK inhibitors with that of biological DMARDs (bDMARDs) in circumstances where conventional synthetic DMARDs (csDMARDs) are ineffective.192–194 A large observational study of the efficacy of commonly used second-line RA drugs confirmed tha…”
MethodPediatric acute lymphoblastic leukemia
Inaba, H., & Mullighan, C. G. (2020) · Haematologica · doi:10.3324/haematol.2020.247031 · Cited by 765
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.112 · Cited by 706
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2016) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 698
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Královics, R. (2016) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 716
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V. R., Bixby, D. L., Blum, W. G., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 648
Self-citationBarbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., Orazi, A., & Tefferi, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0054-y · Cited by 644
Self-citationClassification and Personalized Prognosis in Myeloproliferative Neoplasms
Grinfeld, J., Nangalia, J., Baxter, E. J., Wedge, D. C., Angelopoulos, N., Cantrill, R., Godfrey, A. L., Papaemmanuil, E., Gundem, G., MacLean, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716614 · Cited by 655
Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovšek, S., Mesa, R. A., Kiladjian, J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 592
Genetic Basis of Acute Lymphoblastic Leukemia
Iacobucci, I., & Mullighan, C. G. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7836 · Cited by 560
Guglielmelli, P., Lasho, T. L., Rotunno, G., Mudireddy, M., Mannarelli, C., Nicolosi, M., Pacilli, A., Pardanani, A. D., Rumi, E., Rosti, V., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4886 · Cited by 553
Self-citationLuspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia‐Manero, G., Buckstein, R. J., Santini, V., Díez‐Campelo, M., Finelli, C., Cazzola, M., İlhan, O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908892 · Cited by 551
Self-citationGenomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 570
Passamonti, F., Cattaneo, C. M., Arcaini, L., Bruna, R., Cavo, M., Merli, F., Angelucci, E., Krampera, M., Cairoli, R., Porta, M. G. D., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30251-9 · Cited by 552
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529
Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia
Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., Parks, B., Gars, E., Liedtke, M., Zheng, G. X. Y., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0332-7 · Cited by 498
Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 508
Self-citationBone marrow niches in haematological malignancies
Méndez‐Ferrer, S., Bonnet, D. A., Steensma, D. P., Hasserjian, R. P., Ghobrial, I. M., Gribben, J. G., Andreeff, M., & Krause, D. S. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0245-2 · Cited by 515
Self-citationClinical significance of somatic mutation in unexplained blood cytopenia
Malcovati, L., Gallì, A., Travaglino, E., Ambaglio, I., Rizzo, E., Molteni, E., Elena, C., Ferretti, V. V., Catricalà, S., Bono, E. B., et al. (2017) · Blood · doi:10.1182/blood-2017-01-763425 · Cited by 482
Self-citationHoelzer, D. T., Bassan, R., Dombret, H., Fielding, A. K., Ribera, J., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 473
Integrative detection and analysis of structural variation in cancer genomes
Dixon, J. R., Xu, J., Dileep, V., Zhan, Y., Song, F., Le, V. T., Yardımcı, G. G., Chakraborty, A., Bann, D. V., Wang, Y., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0195-8 · Cited by 452
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S. O., Stahl, M. F., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 494
“in the bone marrow or peripheral blood, any evidence of extramedullary myeloblasts (myeloid sarcoma), or presence of AML defining genetic abnormalities PML::RARA, RUNX1::RUNX1T1, and CBFB:: MYH11 irrespective of blast percentage.(42) Of note, Acute promyelocytic leukemia (APL), usually associated with a PML::RARA tran…”
BackgroundAdvances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 461
Dinardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 476
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
Bowman, R. L., Busque, L., & Levine, R. L. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.011 · Cited by 448
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Pemmaraju, N., Lane, A. A., Sweet, K. L., Stein, A. S., Vasu, S., Blum, W. G., Rizzieri, D. A., Wang, E. S., Duvic, M. A., Sloan, J. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815105 · Cited by 442
Global burden of hematologic malignancies and evolution patterns over the past 30 years
Zhang, N., Wu, J., Wang, Q., Liang, Y., Li, X., Chen, G., Ma, L., Liu, X., & Zhou, F. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00853-3 · Cited by 457
for the COMFORT-I investigators, Verstovšek, S., Mesa, R. A., Gotlib, J. R., Gupta, V. K., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0417-z · Cited by 446
Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations
Loh, P.-R., Genovese, G., Handsaker, R. E., Finucane, H. K., Reshef, Y. A., Palamara, P. F., Birmann, B. M., Talkowski, M. E., Bakhoum, S. F., McCarroll, S. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0321-x · Cited by 423
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 428
“The disease is characterized by erythroid hypoplasia, macrocytic anemia, hypolobated megakaryocytes with <5% bone marrow myeloblasts, <1% circulating peripheral blasts and absence of Auer rods as well as the presence of chromosome 5q deletion.(146) Haploinsufficiency of the genes located in two distinct commonly delet…”
BackgroundMLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 402
Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia
Bottomly, D., Long, N., Schultz, A. R., Kurtz, S. E., Tognon, C. E., Johnson, K., Abel, M., Agarwal, A., Avaylon, S., Benton, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.002 · Cited by 403
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D. W., Yakoub‐Agha, I., Mufti, G. J., Fenaux, P., Sanz, G. F., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 385
Unravelling biology and shifting paradigms in cancer with single-cell sequencing
Baslan, T., & Hicks, J. B. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.58 · Cited by 382
van der Meij, K. R. M., Sistermans, E. A., Macville, M. V. E., Stevens, S. J. C., Bax, C. J., Bekker, M. N., Bilardo, C. M., Boon, E. M. J., Boter, M., Diderich, K. E. M., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.10.005 · Cited by 372
Acute myeloid leukemia: 2019 update on risk‐stratification and management
Estey, E. H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25214 · Cited by 374
Ogawa, S. (2019) · Blood · doi:10.1182/blood-2018-10-844621 · Cited by 382
The genetic basis and cell of origin of mixed phenotype acute leukaemia
Alexander, T., Gu, Z., Iacobucci, I., Dickerson, K. M., Choi, J. K., Xu, B., Payne-Turner, D., Yoshihara, H., Loh, M. L., Horan, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0436-0 · Cited by 369
Self-citationElena, C., Gallì, A., Such, E., Meggendorfer, M., Germing, U., Rizzo, E., Cervera, J., Molteni, E., Fasan, A., Schuler, E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-714030 · Cited by 375
Self-citationLambert, J., Pautas, C., Terré, C., Raffoux, E., Turlure, P., Caillot, D., Legrand, O., Thomas, X., Gardin, C., Gogat, K., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188888 · Cited by 362
A landscape of germ line mutations in a cohort of inherited bone marrow failure patients
Bluteau, O., Sébert, M., Leblanc, T. M., de Latour, R. P., Quentin, S., Lainey, É., Hernandez, L., Dalle, J., de Fontbrune, F. S., Lengliné, É., et al. (2017) · Blood · doi:10.1182/blood-2017-09-806489 · Cited by 352
Tefferi, A., & Barbui, T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26008 · Cited by 365
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D. L. P., Helgason, G. V., & Copland, M. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 365
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. T. (2016) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 348
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., & Reikvam, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082907 · Cited by 365
Passamonti, F., Toni Giorgino, A., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R. S., Gotlib, J. R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.169 · Cited by 358
Self-citationFrom Erythroblasts to Mature Red Blood Cells: Organelle Clearance in Mammals
Moras, M., Lefevre, S. D., & Ostuni, M. A. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.01076 · Cited by 364
Bosch de Basea, M., Thierry-Chef, I., Harbron, R., Hauptmann, M., Byrnes, G., Bernier, M.-O., Le Cornet, L., Dabin, J., Ferro, G., Istad, T. S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02620-0 · Cited by 349
“…to cell lineage and maturation 27,28 , the analyses were conducted using the revised WHO classification of lymphoid and myeloid malignancies 27,28 , focusing on the following groupings, types and subtypes (morphology codes in Supplementary Table 1): • All hematological malignancies,…”
InfluentialChronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hochhaus, A., Saußele, S., Rosti, G., Mahon, F., Janssen, J. J. W. M., Hjorth‐Hansen, H., Richter, J., & Buske, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx219 · Cited by 342
for the European Society for Blood and Marrow Transplantation (EBMT), Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0516-2 · Cited by 354
Krauss, A. C., Gao, X., Li, L., Manning, M. L., Patel, P., Fu, W., Janoria, K. G., Gieser, G., Bateman, D. A., Przepiorka, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2990 · Cited by 336
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Pollyea, D. A., Altman, J. K., Assi, R. E., Bachiashvili, K., Bhatt, V. R., Fathi, A. T., Fedorov, K., Foran, J. M., Gojo, I., Goldberg, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0002 · Cited by 326
Eosinophils from Physiology to Disease: A Comprehensive Review
Ramirez, G. A., Yacoub, M., Ripa, M., Mannina, D., Cariddi, A., Saporiti, N., Ciceri, F., Castagna, A., Colombo, G., & Dagna, L. (2018) · BioMed Research International · doi:10.1155/2018/9095275 · Cited by 320
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Tefferi, A. (2020) · American Journal of Hematology · doi:10.1002/ajh.26050 · Cited by 332
Towards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 319
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Tefferi, A., Guglielmelli, P., Nicolosi, M., Mannelli, F., Mudireddy, M., Bartalucci, N., Finke, C. M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0107-z · Cited by 308
Molecular biomarkers in acute myeloid leukemia
Prada‐Arismendy, J., Arroyave-Ospina, J. C., & Röthlisberger, S. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 317
Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z. G., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 303
Aberrant RNA Splicing in Cancer
Escobar‐Hoyos, L. F., Knorr, K. L. B., & Abdel-Wahab, O. I. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050407 · Cited by 303
Philadelphia chromosome–like acute lymphoblastic leukemia
Tasian, S. K., Loh, M. L., & Hunger, S. P. (2017) · Blood · doi:10.1182/blood-2017-06-743252 · Cited by 299
Malcovati, L., Stevenson, K. E., Papaemmanuil, E., Neuberg, D. S., Bejar, R. L., Boultwood, J., Bowen, D., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 304
Self-citationGenome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers
Duncavage, E. J., Schroeder, M. C., O’Laughlin, M., Wilson, R., MacMillan, S., Bohannon, A. S., Kruchowski, S. S., Garza, J. E., Du, F., Hughes, A. E. O., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024534 · Cited by 299
Platzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30615-0 · Cited by 292
Kanate, A. S., Majhail, N. S., Savani, B. N., Bredeson, C., Champlin, R. E., Crawford, S. W., Giralt, S., LeMaistre, C. F., Marks, D. I., Omel, J. L., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.03.002 · Cited by 293
Life histories of myeloproliferative neoplasms inferred from phylogenies
Williams, N., Lee, J., Mitchell, E., Moore, L., Baxter, E. J., Hewinson, J., Dawson, K. J., Menzies, A., Godfrey, A. L., Green, A. R., et al. (2022) · Nature · doi:10.1038/s41586-021-04312-6 · Cited by 285
Barbui, T., Vannucchi, A. M., Buxhofer‐Ausch, V., Stefano, V. D., Betti, S., Rambaldi, A., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.94 · Cited by 284
Self-citationHuman-level recognition of blast cells in acute myeloid leukaemia with convolutional neural networks
Matek, C., Schwarz, S., Spiekermann, K., & Marr, C. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0101-9 · Cited by 289
Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C. A., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001511 · Cited by 287
Heuser, M., Ofran, Y., Boissel, N., Brunet, S., Craddock, C., Janssen, J. J. W. M., Wierzbowska, A., & Buske, C. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.018 · Cited by 286
Myeloid neoplasms with eosinophilia
Reiter, A., & Gotlib, J. R. (2016) · Blood · doi:10.1182/blood-2016-10-695973 · Cited by 282
Age-related clonal hematopoiesis
Shlush, L. I. (2018) · Blood · doi:10.1182/blood-2017-07-746453 · Cited by 281
Adult Acute Lymphoblastic Leukemia
Paul, S., Kantarjian, H. M., & Jabbour, E. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.010 · Cited by 295
Miller, D. T., Lee, K., Abul‐Husn, N. S., Amendola, L. M., Brothers, K. B., Chung, W. K., Gollob, M. H., GORDON, A. S., Harrison, S. M., Hershberger, R. E., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.04.006 · Cited by 277
Verstovsek, S., Gotlib, J., Mesa, R. A., Vannucchi, A. M., Kiladjian, J.-J., Cervantes, F., Harrison, C. N., Paquette, R., Sun, W., Naim, A., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0527-7 · Cited by 305
Nucleophosmin: from structure and function to disease development
Box, J. K., Paquet, N., Adams, M. N., Boucher, D., Bolderson, E., O'Byrne, K. J., & Richard, D. J. (2016) · BMC Molecular Biology · doi:10.1186/s12867-016-0073-9 · Cited by 287
Mutations in AML: prognostic and therapeutic implications
Dinardo, C. D., & Cortes, J. E. (2016) · Hematology · doi:10.1182/asheducation-2016.1.348 · Cited by 283
Passamonti, F., Grießhammer, M., Palandri, F., Egyed, M., Benevolo, G., Devos, T., Callum, J., Vannucchi, A. M., Şıvgın, S., Bensasson, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30558-7 · Cited by 271
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Rumi, E., & Cazzola, M. (2016) · Blood · doi:10.1182/blood-2016-10-695957 · Cited by 263
Self-citationDiagnosis and Treatment of Myelodysplastic Syndromes
Sekeres, M. A., & Taylor, J. (2022) · JAMA · doi:10.1001/jama.2022.14578 · Cited by 267
Diagnosis and classification of hematologic malignancies on the basis of genetics
Taylor, J., Xiao, W., & Abdel-Wahab, O. I. (2017) · Blood · doi:10.1182/blood-2017-02-734541 · Cited by 260
Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia
Liu, Y., Cheng, Z., Pang, Y., Cui, L., Qian, T., Quan, L., Zhao, H., Shi, J., Ke, X., & Fu, L. N. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0734-5 · Cited by 248
Valent, P., Akin, C., Hartmann, K., Nilsson, G. P., Reiter, A., Hermine, O., Sotlar, K., Sperr, W. R., Escribano, L., George, T. I., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2234 · Cited by 254
Self-citationBaliakas, P., Jeromin, S., Iskas, M., Puiggros, A., Plevová, K., Nguyen‐Khac, F., Davis, Z. A., Rigolin, G. M., Visentin, A., Xochelli, A., et al. (2019) · Blood · doi:10.1182/blood-2018-09-873083 · Cited by 242
Metadata
- Authors
- Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W.
- Affiliations
- Stanford Medicine (US)
- Weill Cornell Medicine (US)
- Massachusetts General Hospital (US)
- University of Cologne (DE)
- Johns Hopkins Medicine (US)
- Section of Hematology/Oncology, University of Chicago, Chicago, IL;
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- University of Pavia (IT)
- University of Chicago (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-05-19
- Volume
- 127
- Issue
- 20
- Pages
- 2391-2405
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2339658711
- Cited by
- 10,119
- References
- 139
- Citations by year
- 2026: 370 · 2025: 615 · 2024: 875 · 2023: 1132 · 2022: 1265 · 2021: 1424 · 2020: 1187 · 2019: 998 · 2018: 954 · 2017: 797 · 2016: 320
- FWCI
- 145.41
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-07-21)
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Funders
- Celgene
- Incyte
- Sysmex Corporation
- Genentech
- Takeda Oncology
- Pharmacyclics
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- WHO classification of hematologic neoplasms, myeloid neoplasms, acute leukemia, diagnostic criteria, prognostic factors, gene expression profiling, next-generation sequencing, immunophenotyping, morphological classification, new disease entity
- MeSH terms
- Down Syndrome, Eosinophilia, Humans, Leukemia, Myeloid, Mastocytosis, Myelodysplastic Syndromes, Myeloproliferative Disorders, World Health Organization, Oncogene Proteins, Fusion, Cell Lineage, Myeloid Cells, Genes, Neoplasm, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
